ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents